Loading...
•
Jun 30, 2022
NeoGenomics Q2 2022 Earnings Report
Reported a 3% increase in consolidated revenue, driven by a 4% rise in Clinical Services revenue, while Pharma Services revenue decreased by 4%.
Key Takeaways
NeoGenomics reported a 3% increase in consolidated revenue for the second quarter of 2022, reaching $125 million. Clinical Services revenue increased by 4% to $106 million, while Pharma Services revenue decreased by 4% to $19 million. The company's net loss for the quarter was $35 million, compared to a net income of $76 million in the same period last year.
Consolidated revenue increased 3% to $125 million.
Clinical Services revenue increased 4% to $106 million.
Pharma Services revenue decreased 4% to $19 million.
Chris Smith was appointed CEO, effective August 15, 2022.
Forward Guidance
NeoGenomics did not provide specific forward guidance in this earnings report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...